Skip to content

Ipsen SA Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Thu, Feb 11, 2027, after the market closes · estimates and history

Ipsen SA · E.IPN.PA · France
Use symbol E.IPN.PA in our API & Excel add-in to retrieve this data ↓
155.40
(-0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 25%
Bubble Risk LOW
Realised Volatility (20D) 21.64%

Ipsen SA Forecast

Ipsen SA short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 21.6% a year, a typical one-standard-deviation range is 150.66–160.14 over a week, 145.69–165.11 over a month and 121.78–189.02 over a year. (Signals as of 5 Nov 2026.)

Ipsen SA Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Ipsen SA
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Ipsen SA
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Ipsen SA
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Ipsen SA
P/E
13.42x
Mid-range vs own history
QoQ −4.9%
YoY +42.8%
now 13.41938.87 low17.78 high
ⓘP/E As of 22 Nov 2026.See Ipsen SA returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Ipsen SA
P/S
1.68x
Mid-range vs own history
QoQ −4.9%
YoY +10.3%
now 1.67641.32 low1.94 high
ⓘP/S As of 22 Nov 2026.See Ipsen SA returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Ipsen SA
P/B
2.74x
Mid-range vs own history
QoQ −4.9%
YoY +9.0%
now 2.73622.2 low3.24 high
ⓘP/B As of 22 Nov 2026.See Ipsen SA returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Ipsen SA
EV/EBITDA
3.61x
Mid-range vs own history
QoQ −5.3%
YoY −8.8%
now 3.60713.16 low4.77 high
ⓘEV/EBITDA As of 22 Nov 2026.See Ipsen SA returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Ipsen SA
EV/Sales
1.55x
Mid-range vs own history
QoQ −5.3%
YoY +6.6%
now 1.54541.23 low1.85 high
ⓘEV/Sales As of 22 Nov 2026.See Ipsen SA returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Ipsen SA
FCF Yield
15.8%
Mid-range vs own history
QoQ +5.1%
YoY +6.4%
now 15.752712.62 low18.57 high
ⓘFCF Yield As of 22 Nov 2026.See Ipsen SA returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Ipsen SA
Earnings Yield
7.5%
Mid-range vs own history
QoQ +5.1%
YoY −30.0%
now 7.45195.62 low11.27 high
ⓘEarnings Yield As of 22 Nov 2026.See Ipsen SA returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Ipsen SA
Dividend Yield
2.8%
Mid-range vs own history
QoQ +5.1%
YoY —
now 2.82792.37 low3.48 high
ⓘDividend Yield As of 22 Nov 2026.See Ipsen SA returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Ipsen SA
Market Cap
$12.9B
Highest in 5 years
QoQ −4.9%
YoY +21.4%
now 12889.2499,543 low14,158 high
ⓘMarket Cap As of 22 Nov 2026.See Ipsen SA returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Ipsen SA
Net Debt
-$1.0B
Low vs own history
QoQ 0.0%
YoY +108.4%
now -1007.1-1,007 low-483.2 high
ⓘNet Debt As of 22 Nov 2026.See Ipsen SA returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Ipsen SA
Net Debt / EBITDA
-0.31x
-0.31x
QoQ 0.0%
YoY +62.1%
now -0.3057-0.31 low-0.19 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Ipsen SA returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Ipsen SA
Current Ratio
1.97x
Strong vs own history
QoQ 0.0%
YoY −0.9%
now 1.96511.96 low1.98 high
ⓘCurrent Ratio As of 22 Nov 2026.See Ipsen SA returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Ipsen SA
Quick Ratio
1.84x
Strong vs own history
QoQ 0.0%
YoY +2.5%
now 1.83921.78 low1.84 high
ⓘQuick Ratio As of 22 Nov 2026.See Ipsen SA returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Ipsen SA
Interest Coverage
31.49x
31.49x
QoQ 0.0%
YoY −12.2%
now 31.488429.88 low35.84 high
ⓘInterest Coverage As of 22 Nov 2026.See Ipsen SA returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Ipsen SA
Debt / Equity
0.20x
Mid-range vs own history
QoQ 0.0%
YoY −10.1%
now 0.20450.2 low0.23 high
ⓘDebt / Equity As of 22 Nov 2026.See Ipsen SA returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Ipsen SA
Piotroski F-Score
5
5
QoQ 0.0%
YoY +25.0%
now 54 low5 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Ipsen SA returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Ipsen SA
Altman Z-Score
5.15
Mid-range vs own history
QoQ −2.7%
YoY +10.8%
now 5.15254.42 low5.45 high
ⓘAltman Z-Score As of 22 Nov 2026.See Ipsen SA returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  12 members-only factors: Estimate Revision 30D, Forward P/E, Gross Margin, EBITDA Margin and moreSign up
Accounting Red Flags
  17 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Ipsen SA, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Ipsen SA fundamentals: income statement, balance sheet & cash flow

Ipsen SA reported revenue of €3.68bn and net income of €444.5m in FY2025, the year ended 31 December 2025 — revenue up 2.8% and net income up 28.5% on the prior year. Free cash flow was €1.03bn. These figures are as reported in the filings, not restated: 24 fiscal years and 84 quarters of history, back to December 2002.

Revenue (FY2025)
€3.68bn
+2.8%
Net income
€444.5m
+28.5%
Gross margin
70.58%
Free cash flow
€1.03bn
+676.8%
Net debt
-€658.4m
Ipsen SA income statement, annual, as reported · EUR millions unless stated
EUR millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue3,675.93,574.53,306.43,156.42,748.6
Cost of revenue1,081.3618.7571.2527.7438.6
Gross profit2,594.62,955.82,735.22,628.72,310.0
Research & development754.0686.6619.3445.3424.4
Selling, general & admin.1,094.31,772.51,299.9——
Operating income746.3496.7816.0943.7886.2
EBITDA1,102.61,161.31,157.61,145.01,059.2
Interest expense36.123.819.423.823.7
Pre-tax income578.2432.2756.1704.4789.5
Income tax133.674.9136.2112.3158.3
Net income444.5345.9644.4648.6646.6

Download Ipsen SA fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.IPN.PA&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 24 fiscal years and 84 quarters, the filing vintages behind each number and API access.
Create free account

Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Ipsen SA

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Ipsen SA Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Ipsen SA; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Ipsen SA’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Ipsen SA behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Ipsen SA (France)

Ipsen SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Ipsen SA?
Ipsen SA is a listed security in France. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Ipsen SA price?
The latest close is 155.4 (5 Nov 2026), -0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Ipsen SA in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is positive (5 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Ipsen SA?
20-day realised volatility is 21.6% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 6.2% over a month and 3.0% over a week.
What factors affect Ipsen SA?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Ipsen SA, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Ipsen SA?
9 backtested tactical asset allocation strategies trade Ipsen SA through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Ipsen SA returns analysed?
The Statistical Distribution of Returns section shows the distribution of Ipsen SA daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Ipsen SA historical data?
In the Free historical data section of this page: the last 10 years of Ipsen SA daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Ipsen SA historical data (last 10 years)

Browse or instantly download the last 10 years of Ipsen SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.IPN.PA&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20161.6
2026-11-19162.4
2026-11-18163
2026-11-17164.1
2026-11-16167.4
2026-11-13166.4
2026-11-12167
2026-11-11167.3
2026-11-10166
2026-11-09163.4
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.